- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
[作者：Baselga, J; Bradbury, I; Eidtmann, H; Di Cosimo, S; de Azambuja, E; Aura, C; Gomez, H; Dinh, P; Fauria, K; Van Dooren, V; Aktan, G; Goldhirsch, A; Chang, TW; Horvath, Z; Coccia-Portugal, M; Domont, J; Tseng, LM; Kunz, G; Sohn, JH; Semiglazov, V; Lerzo, G; Palacova, M; Probachai, V; Pusztai, L; Untch, M; Gelber, RD; Piccart-Gebhart, M,期刊：Lancet, 页码：633-640 , 文章类型： Article，,卷期：2012年379-9816]
- Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast can...
- Pneumonia associated with a dental unit waterline
[作者：Ricci, ML; Fontana, S; Pinci, F; Fiumana, E; Pedna, MF; Farolfi, P; Sabattini, MAB; Scaturro, M,期刊：Lancet, 页码：684-684 , 文章类型： Editorial Material，,卷期：2012年379-9816]
-
- WHO's relationship with the Stop TB Partnership
[作者：Raviglione, M; Nunn, P; Floyd, K; Getahun, H; Grzemska, M; Weil, D; Weyer, K,期刊：Lancet, 页码：611-612 , 文章类型： Letter，,卷期：2012年379-9816]
-
- Atrial fibrillation
[作者：Lip, GYH; Tse, HF; Lane, DA,期刊：Lancet, 页码：648-661 , 文章类型： Article，,卷期：2012年379-9816]
- The management of atrial fibrillation has evolved greatly in the past few years, and many areas have had substantial advances or developments. Recognition of the limitations of aspirin and the availability of new oral an...
|